Previously treated advanced non-small cell lung cancer
Conditions
Interventions
All patients undergo FDG-PET/MRI before and 4 weeks and 9weeks after initiation of anti-PD-1 antibody therapy.
Sponsors
Gunma University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathologically confirmed advanced non-small cell lung cancer (NSCLC), and one or more prior systemic treatment regimens for advanced NSCLC 2) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 3) Patient with evaluable lesion based on RECIST 4) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Pregnant woman 2) Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X-ray. 3) Patients with collagen vascular disease or autoimmune diseases 4) Other cases attending physician it is determined unsuitable for registration of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changeing of SUVmax, MTV and TLG, and the efficacy of anti-PD-1 antibody such as nivolumab or pembrolizumab. Evaluation after 4weeks and 9weeks from administration of anti-PD-1 antibody. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival and progression-free survival | — |
Countries
Japan
Contacts
Public ContactKyochi Kaira
Gunma Univetsity Hospital Inovative medical research center
Outcome results
None listed